Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU (European Union) as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses
Paris, June 23, 2026. The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS)…
